CYP2R1 and myeloid sarcoma: The present study demonstrated that the rs12794714 polymorphism in the CYP2R1 was significantly associated with an increased risk of MS, regardless of 25(OH)D concentrations; this finding revealed its potential as a novel molecular biomarker for predicting the risk of MS in our population.